ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annu... (lasmin. About Vitreomacular Traction...)

HOME >> BIOLOGY >> TECHNOLOGY

ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting

Date:12/4/2007

lasmin."

About Vitreomacular Traction

Numerous conditions are associated with vitreomacular traction which may lead to decreased vision and/or complications. These include macular hole, macular edema (ME) associated with vitreomacular traction, and vitreomacular traction syndrome (VTMS). The only available treatment for these conditions is surgical vitrectomy, in order to induce a posterior vitreous detachment (PVD) and thereby alleviate the vitreomacular traction. Therefore, a pharmacological agent that could relieve vitreomacular traction nonsurgically would be a dramatic advance for the treatment of these conditions, preventing the need for surgery and its associated cost, inconvenience and risk of complications. Macular hole prevalence is approximately 0.14% of general population, leading to estimates of approximately 400,000 cases in the US and of up to 1 million in the industrialized world.

Other potential nonsurgical applications for microplasmin include treatment of macular edema and diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness among working-age adults while diabetic macular edema (DME) is the leading cause of decreased vision in patients with diabetic retinopathy. Around 750,000 patients suffer from DME in the United States alone.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular and eye diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4
Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC

Post Your Comments:

(Date:12/16/2009)... Dec. 16 WaferGen Biosystems, Inc. (OTC ... genetic analysis systems, today announced that it will ... innovative service for gene-expression profiling using its SmartChip(TM) ... provides the most comprehensive human microRNA panel of ... company,s SmartChip service offers customers the use of ...

(Date:12/16/2009)... turn microgears in suspended solution by swimming , ... ... -- Scientists at the U.S. Department of Energy’s (DOE) Argonne ... common bacteria can turn microgears when suspended in a solution, ... energy. , , ,“The gears are a million times more ...

(Date:12/16/2009)... 16 /PRNewswire/ -- Capitalizing ... sciences industry and an active venture capital market, ... State Teachers Retirement Fund, Indiana University, Purdue University, ... Foundation, and Credit Suisse today announced the establishment ... capital fund of funds. ,, Organized through BioCrossroads, ...

(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...

Breaking Biology Technology:WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2 WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3 WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4 Argonne Scientists Use Bacteria to Power Simple Machines 2 Argonne Scientists Use Bacteria to Power Simple Machines 3 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5 Microbix' Pipeline Set To Reach Milestones In 2010 2 Microbix' Pipeline Set To Reach Milestones In 2010 3 Microbix' Pipeline Set To Reach Milestones In 2010 4 Microbix' Pipeline Set To Reach Milestones In 2010 5 Microbix' Pipeline Set To Reach Milestones In 2010 6 Microbix' Pipeline Set To Reach Milestones In 2010 7 Microbix' Pipeline Set To Reach Milestones In 2010 8

[0] WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System [0] Argonne Scientists Use Bacteria to Power Simple Machines [0] Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth [0] Microbix' Pipeline Set To Reach Milestones In 2010

... Sequential Profitable Quarter -- -- Conference Call ... BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... results for the three months and twelve months ended December ... 2007 sales of $33.5 million, up 118% year-over-year ...

... 28 Eisai Co.,Ltd. and its U.S. subsidiary ... States District Court for the District of New,Jersey ... Eisai,s motion for a,preliminary injunction in its patent ... Pharmaceuticals (collectively,"Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride,tablets)., ...

... N.J., March 28 Memory,Pharmaceuticals Corp. (Nasdaq: ... public accounting firm included an explanatory,paragraph in their ... recently filed Annual Report on Form 10-K for ... Company,s ability to continue as a going,concern. The ...

Other Biology Technology:Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7 Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8 Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 2 Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 3 Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification 2

Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification

(Date:12/16/2009)... 9 BIO-key International, Inc. (OTC ... biometric identification solutions, today announced that SC ... security publications, named BIO-key International the 2009 ... Control sub-category Biometrics. ,, (Logo: ... technology editor, SC Magazine, "Biometric providers have ...

(Date:12/15/2009)... 2009 Frost & Sullivan European Border Security ... Securite (Safran Group) for its innovative Automated ... company,s expertise in advanced biometric technology and ... products to end users. ,, (Logo: ... has been involved in delivering identification systems ...

(Date:12/15/2009)... just signed an agreement with the British Society for ... with the journal Biogerontology for an initial ... one member of the Biogerontology editorial board ... Springer will sponsor the society and provide society ... on www.springerlink.com . , Biogerontology offers ...

Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2 BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3 Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2 Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3 Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4 Ikaria 28R 29 Names New Chairman 14523 1 Ikaria 28R 29 Names New Chairman 14523 2 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6 Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7 Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 1 Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 2 Jennerex Inc Receives EMEA Orphan Drug Designation for JX 594 for the Treatment of Hepatocellular Carcinoma 5557 3

[0] BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine [0] Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems [0] Springer signs agreement with British Society of Research on Ageing

... is a defensive, protective reaction. This ancestral and automatic ... potential predator. A new study published in Psychophysiology finds ... encountering a threat. The mere picture of an injured ... unpleasant images, the study's participants froze as their heart ...

... at Yale have identified a gene that regulates the ... according to a recent report in the journal Cell. ... zone of dead cells around an infection site that ... of Molecular, Cellular and Developmental Biology at Yale and ...

... new pan-genome , Ever since the genomics revolution ... numbers of genomes. Cataloging. Analyzing. Comparing. Public databases ... scientists at The Institute for Genomic Research (TIGR) ... the powerful tools of comparative genomics and mathematics, ...

Other Biology News:When in danger humans are similar to a deer in the headlights 2 Researchers predict infinite genomes 2 Researchers predict infinite genomes 3

When in danger humans are similar to a deer in the headlights How cell suicide protects plants from infection Researchers predict infinite genomes

Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...

Component in MasterPure™ Purification Kits...

...

Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...

Biology Products:

Mouse Anti-DcR1 Monoclonal Antibody, Biotin Conjugated, Clone DJR3 from Abcam TE Buffer from EPICENTRE Biotechnologies PAP PEN from Invitrogen TE Buffer Solution, 1X, pH 8.0, sterile from Research Organics, Inc.

ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annu...(lasmin. About Vitreomacular Traction...)